drug discovery and development

Biomarker intelligence comes from understanding the biomarker landscape, that is, the characteristics and features of biomarkers, and disease pathways. This understanding, in turn, helps to recognize the utility of biomarkers. In this study, we partnered with Amplion Inc., to investigate biomarker usage in 24 immunotherapy companies. We found the most popular biomarkers and learnt how they are being used by each company.

Is the hype surrounding biosimilars real or simply a hopeful view on an exceedingly expensive drug market? Read this article to find out more about biosimilars and understand the challenges facing the biosimilars industry.

In this podcast, learn more about biomarkers and their importance in clinical trials and how data-rich tools are being used to collect and curate the vast amounts of publicly available information about biomarkers.

Our resident gene editing expert, Dr. Yann Jouvenot, provides an overview of CRISPR gene editing and how it is affecting how research and development are being performed in the Biotech and Pharma industries.

The typical success rate of a clinical trial is less than ten percent. Pharmaceutical companies are using a variety of methods to save time and reduce costs to get drugs to market faster. Biomarker screening is proving to be an effective way to improve the drug discovery and development process. See one of the ways Pharma companies can identify the most relevant biomarkers.

Our resident gene editing expert, Dr. Yann Jounenvat, provides an overview of the four main gene editing techniques that are being used in life science research today. Learn about the pros and cons of each of method and where they are best applied.

Gene augmentation and antisense therapies treat disease by providing a functional copy of faulty gene or repressing its expression. Find out how gene editing tools, like CRISPR, promise a more permanent cure.

Ligand binding assays are utilized throughout the large-molecule drug development process. However, their robustness, accuracy, and reproducibility depend on the quality of critical reagents. See how you can ensure their consistent characterization, particularly during early drug development stages.

Better model systems and faster, more comprehensive screens are only two of the many ways in which CRISPR is changing the pace of discovery. See how CRISPR is transforming research and development by providing us with tools that were once unimaginable.

Discover how Bio-Rad develops highly specific, high-affinity recombinant monoclonal anti-idiotypic antibodies ideal for use in PK and ADA assays.